Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 24, 2025

UWB1.289

RRID:CVCL_B079
Type: Cell Line

Proper Citation

(RRID:CVCL_B079)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B079

Proper Citation: (RRID:CVCL_B079)

Sex: Female

Defining Citation: PMID:17259345, PMID:25230021, PMID:27397505, PMID:29242379, PMID:30894373, PMID:30971826, PMID:35839778

Comments: Omics: Transcriptome analysis by microarray., Omics: HLA class I peptidome analysis by proteomics., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: UWB1.289

Synonyms: UWB1-289, UWB1289

Cross References: BTO:BTO_0006253, ArrayExpress:E-MTAB-3610, ATCC:CRL-2945, BioGRID_ORCS_Cell_line:1041, BioSample:SAMN03471702, cancercelllines:CVCL_B079, Cell_Model_Passport:SIDM00815, Cosmic-CLP:1480374, DepMap:ACH-001418, EGA:EGAS00001000978, GDSC:1480374, GEO:GSM711714, GEO:GSM1291155, GEO:GSM1670568, Lonza:1665, PharmacoDB:UWB1_289_1650_2019, PRIDE:PXD006939, PRIDE:PXD030304, Wikidata:Q54992390

ID: CVCL_B079

Record Creation Time: 20250131T203048+0000

Record Last Update: 20250131T205114+0000

Ratings and Alerts

No rating or validation information has been found for UWB1.289.

No alerts have been found for UWB1.289.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Rutkowska A, et al. (2024) Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation. Cancer research communications, 4(9), 2427.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine, 5(2), 101376.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. Cancer research communications, 4(12), 3084.

Silva R, et al. (2023) Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer. International journal of cancer, 153(1), 120.

McMellen A, et al. (2023) ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Molecular cancer research : MCR, 21(1), 3.

Quintela M, et al. (2023) In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British journal of cancer, 129(1), 163.

Li Y, et al. (2023) PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell reports. Medicine, 4(12), 101326.

Quintela M, et al. (2023) Bromodomain inhibitor i-BET858 triggers a unique transcriptional

response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical epigenetics, 15(1), 63.

Planas-Paz L, et al. (2023) Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO molecular medicine, 15(4), e16863.

Jiang J, et al. (2022) Systematic illumination of druggable genes in cancer genomes. Cell reports, 38(8), 110400.

Yamamoto TM, et al. (2022) Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular cancer therapeutics, 21(4), 647.

Hromas R, et al. (2022) BRCA1 mediates protein homeostasis through the ubiquitination of PERK and IRE1. iScience, 25(12), 105626.

Tirman S, et al. (2021) Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. Molecular cell, 81(19), 4026.

Bruand M, et al. (2021) Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell reports, 36(3), 109412.

Swift ML, et al. (2021) DSB repair pathway choice is regulated by recruitment of 53BP1 through cell cycle-dependent regulation of Sp1. Cell reports, 34(11), 108840.

Taglialatela A, et al. (2021) REV1-Pol? maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. Molecular cell, 81(19), 4008.

Bellio C, et al. (2019) The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. Cancers, 11(11).

Bellio C, et al. (2019) PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells. Molecular cancer research : MCR, 17(2), 431.

Ding L, et al. (2018) PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell reports, 25(11), 2972.

Nacson J, et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell reports, 24(13), 3513.